Similar articles

• [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].

  Yang BY, Yong WB, Zhu J, Zheng W, Zhang YT, Wang XP, Meng SN. Yang BY, et al. Zhonghua Zhong Liu Za Zhi. 2005 Mar;27(3):174-6. Zhonghua Zhong Liu Za Zhi. 2005. PMID: 15946571 Chinese.
• [5 years of dosage intensification and autologous bone marrow or peripheral stem cell transfusion in malignant lymphoma with a high risk of recurrence].

  Jost LM, Pichert G, Reichlin M, Müller E, Jacky E, Honegger HP, Gmür J, Stahel RA. Jost LM, et al. Schweiz Med Wochenschr. 1993 May 8;123(18):932-40. Schweiz Med Wochenschr. 1993. PMID: 8098878 German.
• [Highly malignant non-Hodgkin's lymphomas].

  Fridrik MA. Fridrik MA. Acta Med Austriaca. 1993;20(3):70-7. Acta Med Austriaca. 1993. PMID: 8368049 Review. German.
• [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].

  Zou GR, Zhang YJ, Xie FY, Zheng W, Li HX, Xia YF, Lin TY, Lu TX. Zou GR, et al. Ai Zheng. 2006 Dec;25(12):1543-9. Ai Zheng. 2006. PMID: 17166383 Chinese.
• [Treatment of aggressive non-Hodgkin's lymphomas].

  López A, Palacio C. López A, et al. Med Clin (Barc). 1998 May 9;110(16):614-8. Med Clin (Barc). 1998. PMID: 9656199 Review. Spanish. No abstract available.